HN
Mitochondria-derived peptide with cytoprotective and anti-apoptotic effects. Lower circulating levels in older people are an observational association and do not by themselves indicate a reason to supplement.
Regulatory status (as of Sept 2026)
Not FDA-approved. Not on the April 2026 503A Category 2 removal list or the July 2026 PCAC agenda.
See the FDA peptide regulatory tracker · Read our July 27, 2026 dispatch on the FDA PCAC peptide vote3 studies referenced · Last reviewed Oct 1, 2026 · Reviewed by The Peptide Dispatch Editorial Team · How we research & label content
Humanin is a compound studied only in animals and lab experiments so far. Mitochondria-derived peptide with cytoprotective and anti-apoptotic effects.
| Half-life | Not established in published research |
|---|---|
| How it's given in studies | Subcutaneous injection |
| Research stage | Preclinical (animal) |
| Dosing | Published research: No published human dosing detailsIn vitro only in the foundational work: humanin and derivative peptides applied to neuronal cell cultures challenged with familial Alzheimer's disease mutations and amyloid-beta. Rodent work uses the S14G analog at microgram-scale doses by non-subcutaneous routes. No human dosing published.Community-reportedCommunity-reported: 1–5 mg, subcutaneous injection |
Published-research dosing is what was given in the cited studies (species and units as reported). Community-reported dosing is what users describe, not from clinical studies. Neither is a recommendation. Not medical advice.
Where each point comes from: Clinicalhuman trials and FDA labels Lab / animalrodent, cell and ex vivo studies Community-reporteduser experience and commonly used protocols, not from clinical studies
In plain terms: It is a small peptide made by mitochondria that protected nerve cells from dying in lab studies. Proposed mechanism, from cell-culture studies: a mitochondrial-derived peptide that protected neuronal cells from death caused by familial Alzheimer's disease genes and amyloid-beta (Hashimoto 2001). Binding to IGFBP-3 and BAX is among its proposed anti-apoptotic mechanisms.
How to read this: Each item below is an effect observed in research subjects in the cited studies — think of Dexter, our stand-in research subject. These are findings from the literature, not results you should expect, and not medical advice.
Community-reportedUsers have reported doses of 1–5 mg (subcutaneous injection). This is not a recommendation.
Community reports are anecdotal, vary widely in product quality and purity, and are not medical advice. Talk to a licensed provider.
New research, FDA peptide updates, and what users are reporting. One email a week. Unsubscribe anytime.
| Peptide | Half-Life | Route | Research Status |
|---|---|---|---|
| Humanin | Unknown | Subcutaneous injection | Preclinical (animal) |
| Epitalon | Unknown | Subcutaneous injection | Preclinical (animal) |
| FOXO4-DRI | Unknown | Subcutaneous injection | Preclinical (animal) |
| GDF-11 | Unknown | Subcutaneous injection | Preclinical (animal) |
| Matrixyl (Palmitoyl Pentapeptide-4) | Topical (not systemically relevant) | Topical | Cosmetic/topical |
Values reflect figures reported in published research. Compare any peptides side-by-side →
This peptide belongs to the Anti-Aging category. View All Anti-Aging Peptides
Metabolic
From Our Affiliated Clinic
1836 Wellness is a physician-supervised clinic in Houston, TX. Discussing a compound on this page is not an offer to prescribe or supply it.
See how it works →Disclosure: The Peptide Dispatch and 1836 Wellness are commonly owned by 1836 Wellness LLC. We may benefit financially if you become a client of 1836 Wellness. Learn more.
Dosing, half-life figures, and mechanism descriptions on this page are compiled from peer-reviewed published research, with the species and study type stated where reported. Figures labeled “Dosing used in published research” describe what was given in those studies and do not constitute dosing recommendations for any human use. Each cited paper is listed with DOI and PubMed links in the References section above. Found an error? Contact us.